Previous Article | Next Article 
Journal of Virology, April 1999, p. 2901-2908, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Interaction of the Human Immunodeficiency Virus
Type 1 Nucleocapsid with Actin
Bindong
Liu,1
Renke
Dai,2
Chun-Juan
Tian,1
Liza
Dawson,1
Robert
Gorelick,3 and
Xiao-Fang
Yu1,*
Department of Molecular Microbiology and
Immunology, Johns Hopkins University School of Hygiene and Public
Health, Baltimore, Maryland 212051;
Laboratory of Molecular Carcinogenesis, National Cancer
Institute, Bethesda, Maryland 208922;
and AIDS Vaccine Program, National Cancer
Institute-Frederick Cancer Research and Development Center,
Frederick, Maryland 217023
Received 28 July 1998/Accepted 14 December 1998
 |
ABSTRACT |
The nucleocapsid (NC) domain of the retrovirus Gag protein plays
several important roles in the viral life cycle, including virus
assembly, viral genomic RNA encapsidation, primer tRNA placement, and
enhancement of viral reverse transcription. In this study, deletion of
NC domain of human immunodeficiency virus type 1 (HIV-1) Gag was found
to drastically reduce virus particle production in CD4+ T
cells. Cellular fractionation experiments showed that although most of
the uncleaved wild-type HIV-1 Gag, unmyristylated Gag, and
p6Gag domain-truncated Gag molecules copurified with the
host cell cytoskeleton, most of the mutant Gag molecules
lacking both the NC and p6Gag domains failed to
cofractionate with cytoskeleton. In wild-type virus-infected cells,
in which the viral protease was active, the cleaved NCp7 copurified
with the cytoskeleton, whereas most of the MAp17 and CAp24 did not.
Monoclonal antibody against actin coimmunoprecipitated full-length Gag
and p6Gag domain-truncated Gag molecules from cell lysates
but failed to precipitate the truncated mutant Gag molecules
lacking NC plus p6Gag. Purified recombinant NCp7, but not
CAp24, was able to bind F-actin in cosedimentation experiments.
Furthermore, wild-type NCp7 and a zinc finger mutant NCp7(F16A), like a
cellular actin-binding protein (the villin headpiece), bound
F-actin in a dose-dependent fashion in vitro. Taken together,
these results suggest that HIV-1 NCp7 can bind F-actin directly and
that interaction between HIV-1 Gag and the actin cytoskeleton through
the NC domain may play an important role in HIV-1 assembly and/or other
steps of the viral life cycle.
 |
INTRODUCTION |
In the case of most retroviruses,
with the possible exception of foamy viruses (3, 23), the
Gag molecule can act alone to direct the assembly and release of
immature virus-like particles (32, 60, 62). Several
functional virus assembly domains in Gag, including a membrane binding
domain (M), an interaction domain (I), and a late virus budding domain
(L) (32, 60, 62), have been proposed to exist. However, with
the exception of membrane targeting and binding, the functions of virus
assembly domains I and L remain to be defined.
The Gag molecule of human immunodeficiency virus type 1 (HIV-1) is
initially synthesized as a 55-kDa polyprotein precursor (Pr55Gag) and subsequently cleaved by the viral protease
encoded in the pol gene region to yield the matrix (MAp17),
capsid (CAp24), nucleocapsid (NCp7), p6Gag, and two spacer
peptides P2 and P1 (30). MAp17 contains a major determinant
for plasma membrane targeting and binding (35), the M
domain; both the N-terminal myristylation (8, 28, 58, 66,
69) and internal (20, 24, 58, 66, 69) amino acid
sequences of MAp17 are important for plasma membrane targeting and
binding. NCp7 can function as an I domain when fused with the Rous
sarcoma virus Gag molecule (5) and is known to be critical
for HIV-1 assembly (15, 19, 54, 67, 68). The L domain of
HIV-1 Gag maps to the p6Gag region, which is required for
efficient virus release (27, 31, 47, 57, 65).
Retroviral Gag molecules are first synthesized in the cytoplasm and
then subsequently transported to the site of virus budding on the
plasma membrane. During transport, Gag molecules directly or
indirectly encounter the host cell cytoskeleton, which comprises microtubule filaments, intermediate filaments, and actin
microfilaments. Increasing evidence is accumulating to indicate that
cytoskeleton components, especially actin microfilaments, play an
important role in HIV-1 assembly. In HIV-1-infected T cells and
macrophages, actin and HIV-1 Gag proteins are colocalized in the
pseudopod structures, where virus budding is concentrated
(48, 50), and interaction between HIV-1 Gag precursor
molecules and actin has been reported (52). Cytochalasin D,
which alters intracellular actin structures (13), also
affects the intracellular distribution of HIV-1 Gag (52) and
partially inhibits HIV-1 production (55). Finally, purified
HIV-1 virions have been shown to contain actin and several
actin-binding proteins (46).
In this study we have analyzed and compared the effects of the three
assembly domains of HIV-1 Gag on virus assembly in CD4+ T
cells, and we have investigated the possible interactions of these
assembly domains with the host cell cytoskeleton. We found that the NC
domain and myristylation of HIV-1 Gag were essential for virus
production from CD4+ T cells, whereas the L domain in
p6Gag enhanced virus production. Mutations that destroyed
myristylation of HIV-1 Gag or the p6Gag domain did not
affect cofractionation of the mutant Gag with the host cell
cytoskeleton, whereas deletion of the NC domain significantly reduced
the cofractionation of the mutant Gag with the cytoskeleton. We found
that purified NC protein was able to bind F-actin directly in vitro.
Furthermore, interaction between full-length HIV-1 Gag and truncated
Gag containing NC but not NC truncated Gag molecules and actin in H9
cells was detected by coimmunoprecipitation experiments, suggesting a
possible link between actin binding and HIV-1 replication.
 |
MATERIALS AND METHODS |
DNA constructs and cells.
The wild-type infectious
proviral plasmid HXB2Neo, the myristylation-minus mutant proviral
plasmid (Myr-), and the pol region deletion
mutant HXB2Neo
Pol (Pr55) proviral plasmid have been previously
described (40, 41). The Pr48 construct is isogenic to
HXB2Neo, except for the presence of a premature stop codon at the
beginning of p6Gag coding region (64). The Pr41
construct is also isogenic to HXB2Neo, except for a premature
stop codon at the end of CAp24 coding region
(15). H9 cell lines expressing each of the viral constructs
were generated and maintained as previously described (40,
41).
Virus production analysis by immunoblotting.
Virus produced
from H9 cells over a period of 24 h was harvested. Cells were
washed twice with phosphate-buffered saline (PBS) to remove released
virions and then resuspended in fresh RPMI 1640 with 10% fetal bovine
serum and antibiotics. After 24 h supernatants were cleared of
cell debris by centrifugation for 10 min at 3,000 rpm in a Sorvall RT
6000B centrifuge, filtered through 0.2-µm-pore-size filters
(Millipore, Bedford, Mass.), and then centrifuged at 100,000 × g over a 20% sucrose cushion in a Sorvall ultracentrifuge with an AH-629 rotor. Viral pellets were resuspended in
radioimmunoprecipitation assay buffer (0.05 M Tris [pH 7.2], 0.15 M
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate [SDS]) at approximately 1/1,000 of the starting supernatant
volume, and the samples were mixed with loading buffer for
SDS-polyacrylamide gel electrophoresis (PAGE) (12% gel). Cell pellets
were collected and lysed in a small volume of radioimmunoprecipitation
assay buffer (approximately 1/100 of the starting supernatant volume). Cell lysates were cleared by centrifugation at 12,000 × g in Eppendorf tubes for 30 min in a tabletop microcentrifuge; the
supernatant from this spin was removed to a fresh tube and mixed with
sample loading buffer for SDS-PAGE (12% gel). Immunoblotting of cell lysates and viral lysates was performed as previously described (40, 41).
Cell fractionation by detergent extraction.
The procedure
for detergent extraction was modified from that of Rey et al.
(52). Cells (5 × 105) were washed once
with 1 ml of PBS by centrifugation at 1,500 rpm for 10 min in a Sorvall
RT 6000B centrifuge and then twice with 50 µl of cytoskeleton
stabilizing buffer [CSB; 100 mM piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES; pH 6.9) with 1 mM EGTA, 3% polyethylene glycol 8000, and
66 µg of phalloidin/ml]. Cell pellets were collected by
centrifugation at 800 × g for 2 min and lysed with 50 µl of CSB containing 1% Triton X-100, 2 mM GTP, aprotinin (2 µg/ml) phenylmethylsulfonyl fluoride (50 µg/ml), and leupeptin (2 µg/ml) by gentle pipetting 10 times. Cell lysates were centrifuged at
800 × g for 5 min. The supernatants (enriched for
cytoplasmic and detergent-soluble membrane fractions) were carefully
separated from the pellets and clarified for 5 min at 1,500 × g, and the resulting supernatants were termed soluble
fractions. The detergent-insoluble pellets were washed twice with 50 µl of CSB (insoluble fraction). The soluble and insoluble fractions
were dissolved in equal volumes of 1× sample buffer (0.08 M Tris-HCl
[pH 6.8] with 2.0% SDS, 10% glycerol, 0.1 M dithiothreitol, and
0.2% bromophenol blue) and analyzed by SDS-PAGE and immunoblotting
with a rabbit polyclonal anti-CAp24 serum (AIDS Research and Reference
Reagent Program, National Institute of Allergy and Infectious Diseases,
National Institutes of Health), a sheep polyclonal anti-MAp17 serum
(AIDS Research and Reference Reagent Program), a monoclonal anti-NCp7 antibody (a gift from Larry Arthur), an HIV-1-positive human antiserum, or a monoclonal antiactin antibody (Sigma, St. Louis, Mo.).
Coimmunoprecipitation experiments.
Cells (5 × 105) were lysed by incubation at room temperature for 10 min in 100 µl of PBS containing 1% Triton X-100, and the cell
lysates were clarified by centrifugation at 8,000 × g
for 20 min. The supernatants were incubated overnight at 4°C with protein A-Sepharose beads that had been preincubated with a monoclonal antiactin antibody (Sigma) or a monoclonal antitubulin antibody (Sigma). The unbound fractions were separated from the Sepharose beads
by centrifugation at 1,000 × g for 2 min. Pellet
samples were washed five times with 500 µl of PBS containing 1%
Triton X-100. To release the immunoprecipitates (bound fraction), the Sepharose beads were boiled in 1× sample buffer for 5 min and then
briefly centrifuged at 12,000 × g. The unbound and
bound fractions were adjusted to equal volumes with 1× sample buffer and separated by SDS-PAGE, and the viral proteins were visualized by
immunoblotting with an HIV-1-positive human serum.
F-actin cosedimentation.
Actin polymerization and F-actin
cosedimentation were performed according to the traditional methods
(43). Chicken muscle actin (Sigma) was stored in monomeric
form in buffer G (5 mM Tris-HCl [pH 7.5] with 0.1 mM CaCl, 0.1 mM
ATP, and 10 mM 2-mercaptoethanol). For measuring the dose response of
wild-type NCp7 (AIDS Research and Reference Reagent Program), F16A
mutant NCp7 [NCp7(F16A)], or villin headpiece (a gift from James
McKnight) binding to actin, G-actin at concentrations of 0, 1.25, 2.5, 5, 10, and 20 µM was subjected to polymerizing conditions (addition
of 50 mM KCl, 1 mM MgCl2, and 1 mM ATP) and incubated
for 1 h at room temperature. Purified NCp7 (2.5 µM) or villin
headpiece (2.5 µM) in buffer G was then added to each actin sample,
and the mixtures were incubated for 30 min at room temperature and then
centrifuged at 150,000 × g for 30 min. The
supernatants and pellets were separated for subsequent analysis by 15%
tricine SDS-PAGE, and the proteins were visualized by Coomassie blue
staining. To compare the actin-binding capacities of CAp24 and NCp7, 50 µM G-actin was subjected to polymerization and then mixed with 1 µg
of CAp24 or NCp7 before ultracentrifugation.
Preparation of NCp7(F16A) protein.
Mutant NCp7 protein was
prepared from a thioredoxin-NCp7 fusion protein as follows. The coding
region for the NCp7(F16A) protein was obtained by PCR amplification of
an HIV-1 MN proviral clone, using the primers F16A-sense (5'-ATG
CCG GGG TAC CGA CGA CGA CAA GAT GCA
GAG AGG CAA TTT TAG GAA TCA AAG AAA GAT TAT CAA GTG Cgc CAA TTG TGG CAA
AGA AGG-3') and F16A-antisense (5'-GGG TAC GGT CGA CCT AAT TAG CCT GTC TCT CAG TAC AAT CTT TCA
TTT GG-3'), obtained from Operon Technologies, Inc., Alameda,
Calif. Oligonucleotide F16A-sense contains a KpnI site
(underlined) and the sequence that codes for the enterokinase cleavage
site (Asp-Asp-Asp-Asp-Lys); the remaining 63 nucleotides (3' end) code
for the 21 N-terminal residues of the HIV-1 NCp7(F16A) protein from the
MN proviral clone (NC protein starts with a Met residue). The location
of the F16A mutation is indicated in lowercase. Oligonucleotide
F16A-antisense contains a SalI site (underlined), the
complement of a TAG stop codon (lowercase), and the complement of
the sequence that codes for the 11 C-terminal residues of NCp7 ending
with an Asn residue. The fragment that codes for the 55-amino-acid NCp7
protein with the enterokinase cleavage site at the N terminus and the
flanking KpnI and SalI sites was prepared by PCR
as follows. The HIV-1 MN proviral plasmid (~50 ng) was amplified by
using AmpliTaq core reagents (Perkin-Elmer, Roche Molecular Systems,
Inc., Branchburg, N.J.), 4 mM MgCl2, 2 µM each
oligonucleotides F16A-sense and F16A-antisense, and AmpliTaq Gold
according to the manufacturer's procedures. Amplification was
performed in a Perkin-Elmer PE9600 thermocycler as follows: incubation
at 94 for 9 min; 35 cycles of 94°C for 10 s, 65°C for 15 s, and 70°C for 30 s; and incubation at 70°C for 8 min. The
primers and nucleotides were removed from the PCR products by dilution
to 200 µl of 10 mM Tris-1.0 mM EDTA (pH 8.0) and centrifugation
through a Microcon 50 column until the volume was ~0.1 that of the
starting volume. This wash procedure was repeated. The retentate was
then digested with KpnI and SalI. The fragment
containing the NCp7 coding region was then ligated into the homologous
sites of the pET32a vector (Novagen, Inc., Madison, Wis.). Plasmids
were screened, and sequences were verified by nucleotide sequence analysis.
Competent Escherichia coli BL21(DE3) was transformed
with plasmid pET32a containing the NCp7(F16A) gene. In a 4-liter
Erlenmeyer flask, 500 ml of LB broth containing 100 µg of ampicillin
per ml was inoculated with the transformed bacteria and grown at 37°C with shaking to an optical density at 600 nm of 0.6. Cultures were
stored at 4°C without shaking overnight. The next day, bacteria were
collected by centrifugation at 3,600 × g in a Beckman
(Fullerton, Calif.) JS-4.2 rotor for 20 min at 4°C. The cell pellet
was suspended in 1 liter of LB broth containing 100 µg of ampicillin
per ml and grown at 37°C with shaking until an optical density at 600 nm of 0.6 was reached. Isopropylthio-
-galactoside was added to a
final concentration of 0.4 mM, and the culture was incubated with
shaking for an additional 3 h. Bacteria were pelleted at 3,600 × g in a Beckman JS-4.2 rotor for 30 min at
4°C. The pellet was suspended in 40 ml of 100 mM CAPS buffer (pH 10)
and sonicated for ~1.5 h in a model SC 101TH sonicating bath (Sonicor
Instrument Corp., Copiague, N.Y.) in two 50-ml polypropylene conical
tubes. The sonicated material was centrifuged 3,600 × g in a Beckman JS-4.2 rotor for 20 min at 4°C, and the pellet
was discarded.
To 10 ml of the supernatant containing the fusion protein, 106 µl of
4 M Tris buffer (pH 8.5), 213 µl of 5 M NaCl, 0.7 µl
of 30 mM zinc
acetate, and 21 µl of 1 M CaCl
2 were added. The
solution
was slowly stirred on a magnetic stirrer, 7 U of EKMax
enterokinase (Invitrogen Corporation, Carlsbad, Calif.) was added,
and
the solution was digested for 3 h at room temperature. Treatment
of the fusion protein with enterokinase liberates NCp7(F16A) mutant
protein of the correct amino acid sequence for the 55-amino-acid
form
(
30). NCp7(F16A) was purified by reverse-phase high-pressure
liquid chromatography using a C
18 reverse-phase column as
described
previously (
30a). The purified NCp7(F16A) was
analyzed for the
correct molecular mass by matrix-assisted laser
description ionization
time-of-flight mass spectrometry using a
Shimadzu Kompact Maldi-II
laser desorption mass spectrometer.
Quantitation of the purified
protein was performed by amino acid
analysis on a Beckman System
6300 amino acid analyzer (Beckman Coulter,
Inc., Fullerton, Calif.).
Purified protein was aliquoted, one
equivalent of zinc acetate
per Zn
2+ finger was added, and
the sample was lyophilized. The dried NCp7(F16A)
sample was stored at

70°C. The mutant protein was dissolved in
buffer
G.
 |
RESULTS |
Mutant constructs and virus production from CD4+ T
cells.
We established CD4+ T cells (H9) containing
various mutant constructs as a means of evaluating the effect of
specific assembly domains of HIV-1 Gag on virus production (Fig.
1A). The full-length HIV-1 Gag containing
all three assembly domains was expressed from the Pr55 construct (Fig.
1). This construct contains a point mutation that destroyed the
activity of viral protease (41). The M-domain mutant was
represented by the Myr- construct. Pr48 contained a truncation of the
p6Gag, the L domain, and the Pr41 contained a truncation of
both the I domain (NCp7) and the L domain.


View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Diagram of truncation mutants of HIV-1 Gag. For
details on construction of mutants, see Materials and Methods.
Construct Pr55 expresses full-length HIV-1 Gag. Myr-contains a mutation
that destroyed the signal for myristylation. Construct Pr48 contains a
stop codon at the beginning of the p6Gag, while Pr41
has a stop codon at the end of the CAp24. LTR, long terminal
repeat. (B) Virus production from H9 cells. Cell and virus lysates from
H9 cells expressing Pr55 and mutant Gag constructs were separated by
SDS-PAGE, transferred to nitrocellulose filters, and analyzed by
immunoblotting with an HIV-1-positive human serum. (C) Cellular
fractionation of viral proteins. Triton X-100-insoluble (I) and
-soluble (S) materials from uninfected H9 cells (H9), and from H9 cells
expressing Pr55 and mutant Gag constructs were prepared as described in
Materials and Methods. Lysates were separated by SDS-PAGE, transferred
to nitrocellulose filters, and analyzed by immunoblotting with a rabbit
polyclonal anti-CAp24 serum.
|
|
H9 cell lines carrying each of the DNA constructs were generated, and
virus production was evaluated. Consistent with previous
observations in a variety of target cells other than CD4
+ T
cells, virus production in cells expressing mutant forms of
Myr-
(Fig.
1B, lane 3) or Pr41 (Fig.
1B, lane 4) Gag molecules
was much
lower than that in cells expressing wild-type Gag molecules
(Fig.
1B,
lane 5). The virus yield from the cells expressing the
mutant Pr48
(Fig.
1B, lane 2) Gag molecules was slightly less
than that from cells
expressing wild-type Gag molecules. It is
expected that there is no Gag
processing in H9 cells expressing
Pr55, Myr-, and Pr41 constructs. The
Pr55 construct contains a
point mutation that has destroyed the
activity of viral protease
(
41). Our previous observations
have indicated that the Myr-
construct has a defect in Gag processing
in H9 cells (
39). The
Pr41 construct does not express Pol
because of a premature stop
codon before the frameshifting signal.
Our group and others have
previously reported that truncation of
p6
Gag (Pr48 construct) results in reduced Gag processing in
COS and
HeLa cells (
31,
64). It seems that this construct
also has
a defect in Gag processing in H9 cells (Fig.
1B).
Cofractionation of various forms of HIV-1 Gag molecules with the
host cell cytoskeleton.
It has been reported that HIV-1 Gag
cofractionates with host cell cytoskeleton (52). To address
the question of whether mutant Gag molecules could influence
cofractionation with the host cell cytoskeleton, we extracted H9 cells
expressing various forms of the Gag molecules with nonionic detergent
and separated the cell extracts into detergent-insoluble
(cytoskeleton-enriched) and detergent-soluble (cytosolic and membrane)
fractions. Most of the wild-type Gag molecules (Pr55) fractionated with
the detergent-insoluble cytoskeleton fraction (Fig. 1C, lane 3); a
small fraction of the wild-type Gag molecules (Pr55) was associated
with the detergent-soluble fraction (Fig. 1C, lane 4). A similar
distribution was observed for the mutant Myr- (Fig. 1C, lanes 5 and 6)
and Pr48 (Fig. 1C, lanes 7 and 8) Gag molecules. In contrast, most of
the mutant Pr41 Gag molecules cosedimented with the detergent-soluble
fraction (Fig. 1C, lane 10), although some still remained associated
with the detergent-insoluble fraction (Fig. 1C, lane 9). The
cytoskeleton fraction purified in this manner contains both
cytoskeleton, cytoskeleton-associated complexes, and unbroken nuclei.
We have examined H9 cells expressing various Gag constructs by
immunofluorescence and have not detected significant accumulation of
wild-type or mutant Gag molecules in the nuclei (data not shown).
Therefore, cofractionation of HIV-1 Gag molecules with the cytoskeleton
fraction is not the result of a nuclear localization of HIV-1 Gag
molecules. However, cofractionation experiments cannot address whether
HIV-1 Gag molecules bind directly or indirectly to the cytoskeleton or
associate with noncytoskeleton complexes which copelleted with the cytoskeleton.
Cofractionation of various cleaved HIV-1 Gag molecules with
the host cell cytoskeleton.
To identify which domain(s)
of the HIV-1 Gag molecule might contribute to
cofractionation with cytoskeleton, we also fractionated HIV-1-infected
H9 cells as described above. In HIV-1-infected H9 cells that expressed
active viral protease, the uncleaved Gag precursor Pr55 as well as the
cleaved Gag proteins MAp17, CAp24, and NCp7 could be detected. Although
most of the uncleaved Gag precursor Pr55 cosedimented with the
cytoskeletal proteins as described above, most of the CAp24
cosedimented with the detergent-soluble fraction (Fig.
2A, upper panel, lane 4). MAp17 was
largely detected in the detergent-soluble fraction (Fig. 2A, middle
panel, lane 4), whereas NCp7 was detected only in the cytoskeleton
fraction (Fig. 2A, lower panel, lane 3). When we analyzed the
distribution of actins in uninfected and HIV-1-infected H9 cells, we
observed that most of the intracellular actins cosedimented with the
detergent-insoluble cytoskeleton (Fig. 2B). HIV-1 infection did not
drastically change the distribution of intracellular actin. These data
suggest that NCp7 is a major determinant for cofractionation of HIV-1
Gag molecule with the host cell cytoskeleton.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
Cellular fractionation of cleaved HIV-1 Gag proteins.
Triton X-100-insoluble (I) and -soluble (S) materials from uninfected
H9 cells (H9) or from wild-type HIV-1-infected H9 cells (H9/HIV-1) were
prepared as described in Materials and Methods. (A) Lysates were
separated by SDS-PAGE, transferred to nitrocellulose filters, and
analyzed by immunoblotting with an HIV-1-positive human serum (top
panel), a sheep anti-MAp17 antiserum (middle panel), or a monoclonal
anti-NCp7 antibody (lower panel). (B) Lysates were separated by
SDS-PAGE, transferred to nitrocellulose filters, and analyzed by
immunoblotting with a monoclonal antiactin antibody.
|
|
Coimmunoprecipitation of HIV-1 Gag and actin from infected
cells with a monoclonal antibody against actin.
To determine
whether HIV-1 Gag molecules could bind actin in infected cells,
we performed coimmunoprecipitation experiments. Cells were lysed with
1% Triton X-100 in PBS, and the detergent-soluble cell lysates were
immunoprecipitated with a monoclonal antiactin antibody that had been
preadsorbed onto protein A-Sepharose beads. The bound and unbound
fractions were dissolved in equal volumes of sample buffer, separated
by SDS-PAGE, and analyzed by immunoblotting with an HIV-1-positive
human serum. The wild-type Gag molecules (Pr55) from H9 cells were
precipitated with the antiactin antibody (Fig.
3A, upper panel, lane 3); some wild-type
Gag molecules (Pr55), however, were not (Fig. 3A, upper panel, lane
4). Similarly, the mutant Pr48 Gag molecules from H9 cells were
precipitated with the antiactin antibody (Fig. 3A, lower panel, lane
5). Since Pr48 comigrated with a protein from mock-infected H9
cells on SDS-12% polyacrylamide gels (Fig. 3A, upper panel), the
original samples were rerun on SDS-10% polyacrylamide gels (Fig. 3A,
lower panel). On 10% gels, both Pr48 and Pr41 could be clearly
separated from background protein bands. In contrast to the results
obtained for Pr55 and Pr48, none of the mutant Pr41 Gag molecules were precipitated with the antiactin antibody (Fig. 3A, lower panel, lane
7). In control experiments, neither wild-type Gag molecules (Pr55),
mutant Pr48 Gag molecules, nor mutant Pr41 Gag molecules were
immunoprecipitated with a monoclonal antitubulin antibody (Fig. 3B).
Furthermore, when no antibody was added to the protein A-Sepharose
beads, neither wild-type Gag molecules (Pr55), mutant Pr48 Gag
molecules, nor mutant Pr41 Gag molecules were detected in the pellet
fractions (Fig. 3C). A 50-kDa protein was detected in all of the
protein A-Sepharose beads pellet fractions (even that from the
uninfected H9 cells) after incubation with antitubulin antibody (Fig.
3B). The precise nature of this protein band is unknown; it was not
detected in the absence of antibody (Fig. 3C) and thus may represent
the heavy chain of the mouse immunoglobulin precipitated by the protein
A-Sepharose beads. The presence of this protein in the immunoblot did
not alter the conclusion drawn from these experiments: that some Pr55
and Pr48 molecules were associated with actin in H9 cells, while the
majority of the Pr41 molecules were not associated with actin in H9
cells.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 3.
Coimmunoprecipitation analysis. Cell lysates from
uninfected H9 cells (lanes 1 and 2) and H9 cells expressing Pr55 (lanes
3 and 4), Pr48 (lanes 5 and 6), and Pr41 (lanes 7 and 8) were prepared
by lysing the cells in PBS containing 1% Triton X-100, followed by
immunoprecipitation with a monoclonal antiactin antibody (A), a
monoclonal antitubulin antibody (B), or no antibody (C). The
immunoprecipitated (bound [B]) and unprecipitated (unbound [U])
materials were separated by SDS-PAGE on a 12% (A, upper panel) or 10%
(A, lower panel) gel and transferred onto two nitrocellulose filters.
Viral proteins on the filters were visualized by immunoblotting with an
HIV-1-positive human serum.
|
|
Direct binding of NCp7, but not CAp24, to F-actin.
Since NCp7
and, to a lesser extent, CAp24 copurified with the cytoskeletal
components, we asked whether purified CAp24 and NCp7 could bind actin
directly. Binding of CAp24 and NCp7 to actin was assayed by measuring
cosedimention with in vitro-polymerized F-actin. Most of the CAp24 did
not cosediment with F-actin after ultracentrifugation (Fig.
4, lane 3) and remained in the
supernatant (Fig. 4, lane 4). At the same time, most of the NCp7
cosedimented with the F-actin pellet (Fig. 4, lane 5), and very little
remained in the supernatant (Fig. 4, lane 6). When CAp24 or NCp7 was
incubated in the same buffer in the absence of actin, no significant
amount of CAp24 (Fig. 4, lane 7) or NCp7 (Fig. 4, lane 8) could be
pelleted, suggesting that under these experimental conditions there was no significant aggregation of CAp24 or NCp7.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 4.
F-actin cosedimentation. Chicken muscle actin (50 µM)
was polymerized as described in Materials and Methods and then mixed
with buffer alone, 1 µg of CAp24, or 1 µg of NCp7 before
ultracentrifugation. The same amount of CAp24 or NCp7 was also
incubated in the actin polymerization buffer in the absence of actin.
The supernatants (S) and pellets (P) were separated after
ultracentrifugation and analyzed by 15% tricine SDS-PAGE; the proteins
were visualized by Coomassie blue staining.
|
|
A more quantitative analysis of NCp7 binding to actin was accomplished
by cosedimentation with various concentrations of F-actin.
With
increasing concentrations of actin, NCp7 was progressively
depleted
from the residual supernatant following ultracentrifugation
(Fig.
5A). Although some binding of NCp7 (2.5 µM) to F-actin in
the ultracentrifugation pellet was detected when
1.25 and 2.5
µM G-actin was used for polymerization (Fig.
5A, lanes 8 and 9),
increased binding of NCp7 to F-actin was detected when 5 µM
or
more G-actin was used for polymerization (Fig.
5A, lanes 10 to
12).
Approximately 40% of the NCp7 bound to F-actin when 10 µM
G-actin
was polymerized to F-actin (Fig.
5A, lane 11). When 20
µM G-actin was
used to polymerize F-actin, more than 70% of the
NCp7 was fractionated
with the F-actin pellet (Fig.
5A, lane 12).
The dose-dependent F-actin
binding by NCp7 was very similar to
that of a known cellular
F-actin-binding protein, villin headpiece
(Fig.
5B). Although the actin
binding experiments performed here
represent a traditional method for
testing and confirming putative
actin-binding proteins (
44,
51), it remains to be demonstrated
that NCp7 and actin binding
are relevant in HIV-1-infected cells.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 5.
Dose-dependent F-actin binding determined by
cosedimentation. Actin at concentrations of 0, 1.25, 2.25, 5, 10, and
20 µM was subjected to polymerizing conditions and incubated with 2.5 µM purified wild-type NCp7 (A), villin headpiece (B), or mutant NCp7
(C) before ultracentrifugation. The supernatants (S) and pellets (P)
were separated after ultracentrifugation and analyzed by 15% tricine
SDS-PAGE; the proteins were visualized by Coomassie blue staining.
|
|
We also studied whether certain mutations in NCp7 could affect
actin binding. Zinc fingers of HIV-1 NC have been shown to
be critical
for viral genomic RNA packaging but not for virus
assembly and release
(
32,
60,
62). We tested the F-actin
binding of one
such mutant form of NCp7F16A (
19). The dose-dependent
F-actin binding by the mutant NCp7(F16A) was very similar to
that
of the wild-type NCp7 (Fig.
5A). These results indicate that
certain
mutations in NC that inhibited viral genomic RNA packaging did
not affect F-actin binding (Fig.
5C), suggesting that there may
not be
a direct link between actin binding and viral RNA packaging.
Further
study is under way to identify structural features of
NCp7 that are
critical for F-actin
binding.
 |
DISCUSSION |
In this study, we demonstrated that the NC domain of HIV-1 Gag is
a major determinant in the process of viral protein association with
the host cell cytoskeleton. Mutations in the other two virus assembly domains, M (myristylation) and L (p6Gag), had
little effect on the association of mutant Gag molecules with
cytoskeletal components. Cellular fractionation experiments using
wild-type virus-infected cells which express active viral protease
indicated that cleaved NCp7 almost exclusively fractionated with the
cytoskeleton. In contrast, the most of the mature MAp17 and CAp24
molecules were not associated with cytoskeleton.
It is possible that the association of HIV-1 Gag molecule with the
cytoskeleton is mediated by the NC domain through actin binding. This
argument is supported by our observation that HIV-1 Gag could be
coprecipitated with actin in cell lysates and that purified NCp7 could
bind directly to F-actin in vitro. The observation that HIV-1 Gag and
actin colocalize to the pseudopod structures of virus-infected T cells
and macrophages (48, 50) is also consistent with the concept
that HIV-1 Gag binds to actin filaments in vivo (52). It is
worth noting that small amounts of MAp17 plus CAp24 (Fig. 1, Pr41) and
mature CAp24 (Fig. 2A) cofractionated with cytoskeletal components. The
crystal structure of the carboxy-terminal region of CAp24 (amino acids
151 to 231) resembles the putative actin-binding subdomain of myosin
(26). Although we did not observe direct binding of CAp24 to
F-actin in vitro (Fig. 4), it is still possible that CAp24 or MAp17
plus CAp24 can bind to actin or actin-binding proteins in vivo and
become associated with the cytoskeleton of the host cell.
Alternatively, CAp24 might bind to other components of the
cytoskeleton, such as microtubules or intermediate filaments, either
directly or indirectly.
Previous studies have indicated that the retroviral NC domain plays
several important roles in the life cycle of the virus. However, the
functional significance of the interaction between HIV-1 NC and actin
remains to be characterized. Binding of the NCp7 domain to actin
filaments could be involved in intracellular transport of
HIV-1 Gag molecules; this idea would be consistent with the observation
that HIV-1 Gag molecules are colocalized with actin to the pseudopods
in virus-infected T cells and macrophages (48, 50).
Truncation of NCp7 also resulted in a lower degree of association of
mutant Gag molecules with the plasma membrane than was observed for the
full-length HIV-1 Gag molecules (54).
Actin binding through the NCp7 domain of HIV-1 Gag molecules could also
play a role in virus assembly and budding. One proposed role for the
retroviral Gag assembly domain I (NC) is to stimulate intermolecular
interaction (5, 62); deletion of the NC domain of HIV-1 Gag
has been shown to drastically reduce virus production (15, 34, 54,
67, 68). Substitution of the HIV-1 NC domain with protein modules
known to interact fully or partially restored virus assembly and
release (68). Interaction among HIV-1 Gag molecules during
virus assembly might be enhanced by binding to actin polymers. Actin
and associated actin-binding proteins might also serve as nucleation
sites for the assembly of Gag molecules. Consistent with this idea, it
has been shown that cytochalasin D, a drug that interferes with
cellular actin structures (13), partially reduces virus
production (55).
It is also possible that actin may serve as a structural component of
HIV-1 particles. Actin has been detected in purified HIV-1
virions at approximately 10% of the molar concentration of Gag
(46). The virus-like structures that are released from cells
expressing NC deletion mutant Gag molecules have a density lower than
those of viruses containing the NC domain (5, 15, 34, 54, 67,
68). Interaction of the NC domain with actin may influence the
packing density (amount of viral protein per unit of lipid) of the
HIV-1 Gag molecules during assembly (5, 62). The interaction
among Gag molecules that is mediated through the MA and CA domains
alone might be less tight than that mediated by MA and CA plus NC and
actin. It is worth mentioning that interaction of NC with RNA has also
been proposed to play a role in virus assembly and in controlling
particle density (5, 7, 10, 15, 34). Interactions between
cleaved NCp7 and actin may also play a structural role in the formation
of HIV-1 core, since NCp7 mutants frequently display abnormal core
structures (1, 6, 12, 19).
Extensive mutational analyses have indicated that the retroviral NC
protein is necessary for encapsidation of viral genomic RNA (56), annealing of the primer tRNA to the viral
genomic primer binding site (4, 17), and formation
of the viral genomic RNA dimer (14, 22). In addition to
their structural roles in virus assembly and maturation, nucleocapsids
from several viruses have been shown to be important during early
stages of viral replication, including minus-strand DNA transfer during
viral DNA synthesis (2, 29, 53), prevention of nonspecific
reverse transcription (29, 37, 42), and enhancement of the
processivity of reverse transcriptase activity (33, 49, 53, 61,
63). As a component of the viral nucleocapsid, NC protein, by
interacting with actin and cellular actin-binding proteins, may enhance
the penetration of the viral nucleocapsid into the cytoplasm after
virus fusion and uncoating. NC is also a member of the viral reverse
transcription complex (59). Therefore, it is also intriguing
to consider that the transport of the complex from the site of virus
entry to the nucleus could be enhanced by interaction between NC and
actin filaments, a strategy used also by other viruses such as
baculoviruses (11, 36).
The complete and partial structures of several cellular F-actin-binding
proteins including the C-terminal 36 amino acids of villin headpiece
(45), yeast cofilin (21), and gelsolin
(9), have been determined by X-ray crystallography or
nuclear magnetic resonance spectroscopy. Among them, no common
structural motif that is critical for F-actin binding has been
identified (44, 51). However, the C-terminal
-helix of
the villin headpiece (18, 25), cofilin (38), and
the F-actin binding S2 subdomain of gelsolin (44, 51) have
been found to be important in the interaction with F-actin, as
demonstrated by mutagenesis studies (18) and synthetic
peptide binding experiments (25). In the case of the villin
headpiece, both positively charged amino acids in the C-terminal
-helix and positively charged amino acids in the N-terminal region
are critical for F-actin binding (18). The nuclear magnetic
resonance structure of the HIV-1 NC-RNA complex reveals beta sheets
representing the zinc knuckle domains and an N-terminal 3-10 helix
(16). NCp7 exhibits very low homology to all known
F-actin-binding proteins and did not reveal any significant structural
similarities with other known F-actin-binding proteins. However, there
are several positively charged amino acids in the 3-10 helix as well as
in the linker region between the two zinc fingers. By analogy to villin
headpiece, some of these positively charged residues in NCp7 could be
involved in F-actin binding. Further study is required to map the NCp7
recognition site for F-actin.
 |
ACKNOWLEDGMENTS |
We thank Susan Craig and Richard McCann for helpful suggestions.
We gratefully acknowledge the generous gifts of anti-p7 antibodies from
Larry Arthur and purified recombinant villin headpiece from James
McKnight. We also thank Alan Rein for the NCp7(F13A)-pET32a expression clone and Bradley P. Kane and Donald G. Johnson for assistance in the production and purification of the NCp7(F16A) protein. The following reagents were obtained through the AIDS Research
and Reference Reagent Program, NIAID, NIH: HIV-1MN p7 from Louis
Henderson; HIV-1SF2 p25/24 Gag from Kathelyn Steimer; and HIV-1 p24
antiserum from Julia Hurwitz.
This work was supported in part by Public Health Service grant AI-35525
from the National Institutes of Health and was sponsored in part by the
National Cancer Institute, Department of Health and Human Services
under contract NO1-CO-56000 with SAIC Frederick.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Microbiology and Immunology, Johns Hopkins University School of Hygiene and Public Health, Room E4012, 615 N. Wolfe St., Baltimore, MD 21205. Phone: (410) 955-3768. Fax: (410) 614-8263. E-mail: xfyu{at}jhsph.edu.
 |
REFERENCES |
| 1.
|
Aldovini, A., and R. A. Young.
1990.
Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus.
J. Virol.
64:1920-1926[Abstract/Free Full Text].
|
| 2.
|
Allain, B.,
M. Lapadat-Tapolsky,
C. Berlioz, and J. L. Darlix.
1994.
Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome.
EMBO J.
13:973-981[Medline].
|
| 3.
|
Baldwin, D. N., and M. L. Linial.
1998.
The roles of Pol and Env in the assembly pathway of human foamy virus.
J. Virol.
72:3658-3665[Abstract/Free Full Text].
|
| 4.
|
Barat, C.,
O. Schatz,
S. Le Grice, and J. L. Darlix.
1993.
Analysis of the interactions of HIV1 replication primer tRNA(Lys,3) with nucleocapsid protein and reverse transcriptase.
J. Mol. Biol.
231:185-190[Medline].
|
| 5.
|
Bennett, R. P.,
T. D. Nelle, and J. W. Wills.
1993.
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
67:6487-6498[Abstract/Free Full Text].
|
| 6.
|
Berthoux, L.,
C. Pechoux,
M. Ottmann,
G. Morel, and J. L. Darlix.
1997.
Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis.
J. Virol.
71:6973-6981[Abstract].
|
| 7.
|
Bowzard, J. B.,
R. B. Bennett,
N. K. Krishna,
S. M. Ernst,
A. Rein, and J. W. Wills.
1998.
Importance of basic residues in nucleocapsid sequence for retrovirus Gag assembly and complementation rescue.
J. Virol.
72:9034-9044[Abstract/Free Full Text].
|
| 8.
|
Bryant, M., and L. Ratner.
1990.
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.
Proc. Natl. Acad. Sci. USA
87:523-527[Abstract/Free Full Text].
|
| 9.
|
Burtnick, L. D.,
E. K. Koepf,
J. Grimes,
E. Y. Jones,
D. I. Stuart,
P. J. McLaughlin, and R. C. Robinson.
1997.
The crystal structure of plasma gelsolin: implications for actin severing, capping, and nucleation.
Cell
90:661-670[Medline].
|
| 10.
|
Campbell, S., and V. M. Vogt.
1995.
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.
J. Virol.
69:6487-6497[Abstract].
|
| 11.
|
Charlton, C. A., and L. E. Volkman.
1993.
Penetration of Autographa californica nuclear polyhedrosis virus nucleocapsids into IPLB Sf 21 cells induces actin cable formation.
Virology
197:245-254[Medline].
|
| 12.
|
Clavel, F., and J. M. Orenstein.
1990.
A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology.
J. Virol.
64:5230-5234[Abstract/Free Full Text].
|
| 13.
|
Cooper, J. A.
1987.
Effects of cytochalasin and phalloidin on actin.
J. Cell Biol.
105:1473-1478[Free Full Text].
|
| 14.
|
Darlix, J. L.,
C. Gabus,
M. T. Nugeyre,
F. Clavel, and F. Barre-Sinoussi.
1990.
Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1.
J. Mol. Biol.
216:689-699[Medline].
|
| 15.
|
Dawson, L., and X. F. Yu.
1998.
The role of nucleocapsid of HIV-1 in virus assembly.
Virology
251:141-157[Medline].
|
| 16.
|
De Guzman, R. N.,
Z. R. Wu,
C. C. Stalling,
L. Pappalardo,
P. N. Borer, and M. F. Summers.
1998.
Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element.
Science
279:384-388[Abstract/Free Full Text].
|
| 17.
|
De Rocquigny, H.,
C. Gabus,
A. Vincent,
M. C. Fournie-Zaluski,
B. Roques, and J. L. Darlix.
1992.
Viral RNA annealing activities of human immunodeficiency virus type 1 nucleocapsid protein require only peptide domains outside the zinc fingers.
Proc. Natl. Acad. Sci. USA
89:6472-6476[Abstract/Free Full Text].
|
| 18.
|
Doering, D. S., and P. Matsudaira.
1996.
Cysteine scanning mutagenesis at 40 of 76 positions in villin headpiece maps the F-actin binding site and structural features of the domain.
Biochemistry
35:12677-12685[Medline].
|
| 19.
|
Dorfman, T.,
J. Luban,
S. P. Goff,
W. A. Haseltine, and H. G. Gottlinger.
1993.
Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein.
J. Virol.
67:6159-6169[Abstract/Free Full Text].
|
| 20.
|
Facke, M.,
A. Janetzko,
R. L. Shoeman, and H. G. Krausslich.
1993.
A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum.
J. Virol.
67:4972-4980[Abstract/Free Full Text].
|
| 21.
|
Fedorov, A. A.,
P. Lappalainen,
E. V. Fedorov,
D. G. Drubin, and S. C. Almo.
1997.
Structure determination of yeast cofilin.
Nat. Struct. Biol.
4:366-369[Medline]. (Letter.)
|
| 22.
|
Feng, Y. X.,
T. D. Copeland,
L. E. Henderson,
R. J. Gorelick,
W. J. Bosche,
J. G. Levin, and A. Rein.
1996.
HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro.
Proc. Natl. Acad. Sci. USA
93:7577-7581[Abstract/Free Full Text].
|
| 23.
|
Fischer, N.,
M. Heinkelein,
D. Lindemann,
J. Enssle,
C. Baum,
E. Werder,
H. Zentgraf,
J. G. Muller, and A. Rethwilm.
1998.
Foamy virus particle formation.
J. Virol.
72:1610-1615[Abstract/Free Full Text].
|
| 24.
|
Freed, E. O.,
J. M. Orenstein,
A. J. Buckler-White, and M. A. Martin.
1994.
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.
J. Virol.
68:5311-5320[Abstract/Free Full Text].
|
| 25.
|
Friederich, E.,
K. Vancompernolle,
C. Huet,
M. Goethals,
J. Finidori,
J. Vandekerckhove, and D. Louvard.
1992.
An actin-binding site containing a conserved motif of charged amino acid residues is essential for the morphogenic effect of villin.
Cell
70:81-92[Medline].
|
| 26.
|
Gamble, T. R.,
S. Yoo,
F. F. Vajdos,
U. K. von Schwedler,
D. K. Worthylake,
H. Wang,
J. P. McCutcheon,
W. I. Sundquist, and C. P. Hill.
1997.
Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein.
Science
278:849-853[Abstract/Free Full Text].
|
| 27.
|
Göttlinger, H. G.,
T. Dorfman,
J. G. Sodroski, and W. A. Haseltine.
1991.
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.
Proc. Natl. Acad. Sci. USA
88:3195-3199[Abstract/Free Full Text].
|
| 28.
|
Göttlinger, H. G.,
J. G. Sodroski, and W. A. Haseltine.
1989.
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
86:5781-5787[Abstract/Free Full Text].
|
| 29.
|
Guo, J.,
L. E. Henderson,
J. Bess,
B. Kane, and J. G. Levin.
1997.
Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA.
J. Virol.
71:5178-5188[Abstract].
|
| 30.
|
Henderson, L. E.,
M. A. Bowers,
R. C. N. Sowder,
S. A. Serabyn,
D. G. Johnson,
J. W. Bess, Jr.,
L. O. Arthur,
D. K. Bryant, and C. Fenselau.
1992.
Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.
J. Virol.
66:1856-1865[Abstract/Free Full Text].
|
| 30a.
|
Henderson, L. E.,
R. Sowder,
T. D. Copeland,
G. Smythers, and S. Oroszlan.
1984.
Quantitative separation of murine leukemia virus proteins by reversed-phase high-pressure liquid chromatography reveals newly described gag and env cleavage products.
J. Virol.
52:492-500[Abstract/Free Full Text].
|
| 31.
|
Huang, M.,
J. M. Orenstein,
M. A. Martin, and E. O. Freed.
1995.
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.
J. Virol.
69:6810-6818[Abstract].
|
| 32.
|
Hunter, E.
1994.
Macromolecular interations in the assembly of HIV and other retroviruses.
Semin. Virol.
5:71-83.
|
| 33.
|
Ji, X.,
G. J. Klarmann, and B. D. Preston.
1996.
Effect of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro.
Biochemistry
35:132-143[Medline].
|
| 34.
|
Jowett, J. B.,
D. J. Hockley,
M. V. Nermut, and I. M. Jones.
1992.
Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation.
J. Gen. Virol.
73:3079-3086[Abstract/Free Full Text]. (Erratum, 74:943, 1993.)
|
| 35.
|
Krausslich, H. G., and R. Welker.
1996.
Intracellular transport of retroviral capsid components.
Curr. Top. Microbiol. Immunol.
214:25-63[Medline].
|
| 36.
|
Lanier, L. M., and L. E. Volkman.
1998.
Actin binding and nucleation by Autographa california M nucleopolyhedrovirus.
Virology
243:167-177[Medline].
|
| 37.
|
Lapadat-Tapolsky, M.,
C. Gabus,
M. Rau, and J. L. Darlix.
1997.
Possible roles of HIV-1 nucleocapsid protein in the specificity of proviral DNA synthesis and in its variability.
J. Mol. Biol.
268:250-260[Medline].
|
| 38.
|
Lappalainen, P.,
E. V. Fedorov,
A. A. Fedorov,
S. C. Almo, and D. G. Drubin.
1997.
Essential functions and actin-binding surfaces of yeast cofilin revealed by systematic mutagenesis.
EMBO J.
16:5520-5530[Medline].
|
| 39.
|
Lee, Y.-M.,
C.-J. Tian, and X.-F. Yu.
1998.
A bipartite membrane-binding signal in the human immunodeficiency virus type-1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner.
J. Virol.
72:9061-9068[Abstract/Free Full Text].
|
| 40.
|
Lee, Y. M.,
X. B. Tang,
L. M. Cimakasky,
J. E. Hildreth, and X.-F. Yu.
1997.
Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes.
J. Virol.
71:1443-1452[Abstract].
|
| 41.
|
Lee, Y. M., and X.-F. Yu.
1998.
Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells.
Virology
243:78-93[Medline].
|
| 42.
|
Li, X.,
Y. Quan,
E. J. Arts,
Z. Li,
B. D. Preston,
H. de Rocquigny,
B. P. Roques,
J. L. Darlix,
L. Kleiman,
M. A. Parniak, and M. A. Wainberg.
1996.
Human immunodeficiency virus type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNALys3 in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site.
J. Virol.
70:4996-5004[Abstract/Free Full Text].
|
| 43.
|
McCann, R. O., and S. W. Craig.
1997.
The I/LWEQ module: a conserved sequence that signifies F-actin binding in functionally diverse proteins from yeast to mammals.
Proc. Natl. Acad. Sci. USA
94:5679-5684[Abstract/Free Full Text].
|
| 44.
|
McGough, A.
1998.
F-actin-binding proteins.
Curr. Opin. Struct. Biol.
8:166-176[Medline].
|
| 45.
|
McKnight, C. J.,
P. T. Matsudaira, and P. S. Kim.
1997.
NMR structure of the 35-residue villin headpiece subdomain.
Nat. Struct. Biol.
4:180-184[Medline]. (Letter.)
|
| 46.
|
Ott, D. E.,
L. V. Coren,
B. P. Kane,
L. K. Busch,
D. G. Johnson,
R. C. N. Sowder,
E. N. Chertova,
L. O. Arthur, and L. E. Henderson.
1996.
Cytoskeletal proteins inside human immunodeficiency virus type 1 virions.
J. Virol.
70:7734-7743[Abstract].
|
| 47.
|
Parent, L. J.,
R. P. Bennett,
R. C. Craven,
T. D. Nelle,
N. K. Krishna,
J. B. Bowzard,
C. B. Wilson,
B. A. Puffer,
R. C. Montelaro, and J. W. Wills.
1995.
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
69:5455-5460[Abstract].
|
| 48.
|
Pearce-Pratt, R.,
D. Malamud, and D. M. Phillips.
1994.
Role of the cytoskeleton in cell-to-cell transmission of human immunodeficiency virus.
J. Virol.
68:2898-2905[Abstract/Free Full Text].
|
| 49.
|
Peliska, J. A.,
S. Balasubramanian,
D. P. Giedroc, and S. J. Benkovic.
1994.
Recombinant HIV-1 nucleocapsid protein accelerates HIV-1 reverse transcriptase catalyzed DNA strand transfer reactions and modulates RNase H activity.
Biochemistry
33:13817-13823[Medline].
|
| 50.
|
Perotti, M. E.,
X. Tan, and D. M. Phillips.
1996.
Directional budding of human immunodeficiency virus from monocytes.
J. Virol.
70:5916-5921[Abstract].
|
| 51.
|
Puius, Y. A.,
N. M. Mahoney, and S. C. Almo.
1998.
The modular structure of actin-regulatory proteins.
Curr. Opin. Cell Biol.
10:23-34[Medline].
|
| 52.
|
Rey, O.,
J. Canon, and P. Krogstad.
1996.
HIV-1 Gag protein associates with F-actin present in microfilaments.
Virology
220:530-534[Medline].
|
| 53.
|
Rodriguez-Rodriguez, L.,
Z. Tsuchihashi,
G. M. Fuentes,
R. A. Bambara, and P. J. Fay.
1995.
Influence of human immunodeficiency virus nucleocapsid protein on synthesis and strand transfer by the reverse transcriptase in vitro.
J. Biol. Chem.
270:15005-15011[Abstract/Free Full Text].
|
| 54.
|
Sandefur, S.,
V. Varthakavi, and P. Spearman.
1998.
The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag.
J. Virol.
72:2723-2732[Abstract/Free Full Text].
|
| 55.
|
Sasaki, H.,
M. Nakamura,
T. Ohno,
Y. Matsuda,
Y. Yuda, and Y. Nonomura.
1995.
Myosin-actin interaction plays an important role in human immunodeficiency virus type 1 release from host cells.
Proc. Natl. Acad. Sci. USA
92:2026-2030[Abstract/Free Full Text].
|
| 56.
|
Schlesinger, S.,
S. Makino, and M. L. Linial.
1994.
cis-acting genomic elements and trans-acting proteins involved in the assembly of RNA viruses.
Semin. Virol.
5:39-49.
|
| 57.
|
Schwartz, M. D.,
R. J. Geraghty, and A. T. Panganiban.
1996.
HIV-1 particle release mediated by Vpu is distinct from that mediated by p6.
Virology
224:302-309[Medline].
|
| 58.
|
Spearman, P.,
J. J. Wang,
N. Vander Heyden, and L. Ratner.
1994.
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly.
J. Virol.
68:3232-3242[Abstract/Free Full Text].
|
| 59.
|
Stevenson, M.
1996.
Portals of entry: uncovering HIV nuclear transport pathways.
Trends Cell Biol.
6:9-15.
|
| 60.
|
Swanstrom, R., and J. Wills.
1998.
Synthesis, assembly, and processing of viral proteins, p. 263-334.
In
J. Coffin, S. Hughes, and H. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 61.
|
Tanchou, V.,
C. Gabus,
V. Rogemond, and J. L. Darlix.
1995.
Formation of stable and functional HIV-1 nucleoprotein complexes in vitro.
J. Mol. Biol.
252:563-571[Medline].
|
| 62.
|
Wills, J. W., and R. C. Craven.
1991.
Form, function, and use of retroviral gag proteins.
AIDS
5:639-654[Medline]. (Editorial.)
|
| 63.
|
Wu, W.,
L. E. Henderson,
T. D. Copeland,
R. J. Gorelick,
W. J. Bosche,
A. Rein, and J. G. Levin.
1996.
Human immunodeficiency virus type 1 nucleocapsid protein reduces reverse transcriptase pausing at a secondary structure near the murine leukemia virus polypurine tract.
J. Virol.
70:7132-7142[Abstract/Free Full Text].
|
| 64.
|
Yu, X.-F.,
L. Dawson,
C. J. Tian,
C. Flexner, and M. Dettenhofer.
1998.
Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly.
J. Virol.
72:3412-3417[Abstract/Free Full Text].
|
| 65.
|
Yu, X.-F.,
Z. Matsuda,
Q. C. Yu,
T. H. Lee, and M. Essex.
1995.
Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation.
J. Gen. Virol.
76:3171-3179[Abstract/Free Full Text].
|
| 66.
|
Yuan, X.,
X. Yu,
T. H. Lee, and M. Essex.
1993.
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor.
J. Virol.
67:6387-6394[Abstract/Free Full Text].
|
| 67.
|
Zhang, Y., and E. Barklis.
1997.
Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation.
J. Virol.
71:6765-6776[Abstract].
|
| 68.
|
Zhang, Y.,
H. Qian,
Z. Love, and E. Barklis.
1998.
Analysis of the assembly function of the human immunodeficiency virus type 1 Gag protein nucleocapsid domain.
J. Virol.
72:1782-1789[Abstract/Free Full Text].
|
| 69.
|
Zhou, W.,
L. J. Parent,
J. W. Wills, and M. D. Resh.
1994.
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.
J. Virol.
68:2556-2569[Abstract/Free Full Text].
|
Journal of Virology, April 1999, p. 2901-2908, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Chan, E. Y., Sutton, J. N., Jacobs, J. M., Bondarenko, A., Smith, R. D., Katze, M. G.
(2009). Dynamic Host Energetics and Cytoskeletal Proteomes in Human Immunodeficiency Virus Type 1-Infected Human Primary CD4 Cells: Analysis by Multiplexed Label-Free Mass Spectrometry. J. Virol.
83: 9283-9295
[Abstract]
[Full Text]
-
Houzet, L., Morichaud, Z., Didierlaurent, L., Muriaux, D., Darlix, J.-L., Mougel, M.
(2008). Nucleocapsid mutations turn HIV-1 into a DNA-containing virus. Nucleic Acids Res
36: 2311-2319
[Abstract]
[Full Text]
-
Larsen, L. S. Z., Beliakova-Bethell, N., Bilanchone, V., Zhang, M., Lamsa, A., DaSilva, R., Hatfield, G. W., Nagashima, K., Sandmeyer, S.
(2008). Ty3 Nucleocapsid Controls Localization of Particle Assembly. J. Virol.
82: 2501-2514
[Abstract]
[Full Text]
-
Jolly, C., Mitar, I., Sattentau, Q. J.
(2007). Requirement for an Intact T-Cell Actin and Tubulin Cytoskeleton for Efficient Assembly and Spread of Human Immunodeficiency Virus Type 1. J. Virol.
81: 5547-5560
[Abstract]
[Full Text]
-
Kim, J.-K., Fahad, A.-M., Shanmukhappa, K., Kapil, S.
(2006). Defining the Cellular Target(s) of Porcine Reproductive and Respiratory Syndrome Virus Blocking Monoclonal Antibody 7G10. J. Virol.
80: 689-696
[Abstract]
[Full Text]
-
Jin, S., Chen, C., Montelaro, R. C.
(2005). Equine Infectious Anemia Virus Gag p9 Function in Early Steps of Virus Infection and Provirus Production. J. Virol.
79: 8793-8801
[Abstract]
[Full Text]
-
Mueller, S. M., Jung, R., Weiler, S., Lang, S. M.
(2004). Vpx proteins of SIVmac239 and HIV-2ROD interact with the cytoskeletal protein {alpha}-actinin 1. J. Gen. Virol.
85: 3291-3303
[Abstract]
[Full Text]
-
Beausejour, Y., Tremblay, M. J.
(2004). Interaction between the Cytoplasmic Domain of ICAM-1 and Pr55Gag Leads to Acquisition of Host ICAM-1 by Human Immunodeficiency Virus Type 1. J. Virol.
78: 11916-11925
[Abstract]
[Full Text]
-
Hemonnot, B., Cartier, C., Gay, B., Rebuffat, S., Bardy, M., Devaux, C., Boyer, V., Briant, L.
(2004). The Host Cell MAP Kinase ERK-2 Regulates Viral Assembly and Release by Phosphorylating the p6gag Protein of HIV-1. J. Biol. Chem.
279: 32426-32434
[Abstract]
[Full Text]
-
Chatel-Chaix, L., Clement, J.-F., Martel, C., Beriault, V., Gatignol, A., DesGroseillers, L., Mouland, A. J.
(2004). Identification of Staufen in the Human Immunodeficiency Virus Type 1 Gag Ribonucleoprotein Complex and a Role in Generating Infectious Viral Particles. Mol. Cell. Biol.
24: 2637-2648
[Abstract]
[Full Text]
-
Chen, C., Weisz, O. A., Stolz, D. B., Watkins, S. C., Montelaro, R. C.
(2004). Differential Effects of Actin Cytoskeleton Dynamics on Equine Infectious Anemia Virus Particle Production. J. Virol.
78: 882-891
[Abstract]
[Full Text]
-
Graham, D. R. M., Chertova, E., Hilburn, J. M., Arthur, L. O., Hildreth, J. E. K.
(2003). Cholesterol Depletion of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus with {beta}-Cyclodextrin Inactivates and Permeabilizes the Virions: Evidence for Virion-Associated Lipid Rafts. J. Virol.
77: 8237-8248
[Abstract]
[Full Text]
-
Zhang, J., Crumpacker, C. S.
(2002). Human Immunodeficiency Virus Type 1 Nucleocapsid Protein Nuclear Localization Mediates Early Viral mRNA Expression. J. Virol.
76: 10444-10454
[Abstract]
[Full Text]
-
Serhan, F., Jourdan, N., Saleun, S., Moullier, P., Duisit, G.
(2002). Characterization of Producer Cell-Dependent Restriction of Murine Leukemia Virus Replication. J. Virol.
76: 6609-6617
[Abstract]
[Full Text]
-
Gurer, C., Cimarelli, A., Luban, J.
(2002). Specific Incorporation of Heat Shock Protein 70 Family Members into Primate Lentiviral Virions. J. Virol.
76: 4666-4670
[Abstract]
[Full Text]
-
Le Blanc, I., Blot, V., Bouchaert, I., Salamero, J., Goud, B., Rosenberg, A. R., Dokhelar, M.-C.
(2002). Intracellular Distribution of Human T-Cell Leukemia Virus Type 1 Gag Proteins Is Independent of Interaction with Intracellular Membranes. J. Virol.
76: 905-911
[Abstract]
[Full Text]
-
Lindwasser, O. W., Resh, M. D.
(2001). Multimerization of Human Immunodeficiency Virus Type 1 Gag Promotes Its Localization to Barges, Raft-Like Membrane Microdomains. J. Virol.
75: 7913-7924
[Abstract]
[Full Text]
-
Mariani, R., Rasala, B. A., Rutter, G., Wiegers, K., Brandt, S. M., Kräusslich, H.-G., Landau, N. R.
(2001). Mouse-Human Heterokaryons Support Efficient Human Immunodeficiency Virus Type 1 Assembly. J. Virol.
75: 3141-3151
[Abstract]
[Full Text]
-
Hioe, C. E., Chien, P. C. Jr., Lu, C., Springer, T. A., Wang, X.-H., Bandres, J., Tuen, M.
(2001). LFA-1 Expression on Target Cells Promotes Human Immunodeficiency Virus Type 1 Infection and Transmission. J. Virol.
75: 1077-1082
[Abstract]
[Full Text]
-
Bowzard, J. B., Visalli, R. J., Wilson, C. B., Loomis, J. S., Callahan, E. M., Courtney, R. J., Wills, J. W.
(2000). Membrane Targeting Properties of a Herpesvirus Tegument Protein-Retrovirus Gag Chimera. J. Virol.
74: 8692-8699
[Abstract]
[Full Text]
-
Lu, Y. E., Kielian, M.
(2000). Semliki Forest Virus Budding: Assay, Mechanisms, and Cholesterol Requirement. J. Virol.
74: 7708-7719
[Abstract]
[Full Text]
-
Jewell, N. A., Mansky, L. M.
(2000). In the beginning: genome recognition, RNA encapsidation and the initiation of complex retrovirus assembly. J. Gen. Virol.
81: 1889-1899
[Full Text]
-
Mouland, A. J., Mercier, J., Luo, M., Bernier, L., DesGroseillers, L., Cohen, E. A.
(2000). The Double-Stranded RNA-Binding Protein Staufen Is Incorporated in Human Immunodeficiency Virus Type 1: Evidence for a Role in Genomic RNA Encapsidation. J. Virol.
74: 5441-5451
[Abstract]
[Full Text]
-
Beatch, M. D., Hobman, T. C.
(2000). Rubella Virus Capsid Associates with Host Cell Protein p32 and Localizes to Mitochondria. J. Virol.
74: 5569-5576
[Abstract]
[Full Text]
-
Parker, S. D., Hunter, E.
(2000). A Cell-Line-Specific Defect in the Intracellular Transport and Release of Assembled Retroviral Capsids. J. Virol.
74: 784-795
[Abstract]
[Full Text]